<DOC>
	<DOCNO>NCT02771340</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , biological activity , pharmacokinetics pharmacodynamic activity single repeat escalate intravitreal dos ICON-1 patient primary uveal melanoma plan undergo enucleation brachytherapy affect eye .</brief_summary>
	<brief_title>Study Evaluating Single Repeated Intravitreal Doses ICON-1 Patients With Uveal Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Choroid Neoplasms</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Males female race least 18 year age Clinical diagnosis primary uveal melanoma involve posterior uveal tract study eye Planned enucleation brachytherapy study eye due uveal melanoma Uveal melanoma study eye originate anterior uveal tract ( iris ) Hereditary chronic hemorrhagic coagulopathy condition ( i.e. , hemophilia ) Woman pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>